The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Statera BioPharma's current ratio for the quarter that ended in Sep. 2022 was 0.05.
Statera BioPharma has a current ratio of 0.05. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Statera BioPharma has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Statera BioPharma's Current Ratio or its related term are showing as below:
STU:7CB'
s Current Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.12 Max: 1.31
Current: 0.05
During the past 3 years, Statera BioPharma's highest Current Ratio was 1.31. The lowest was 0.05. And the median was 0.12.
STU:7CB's Current Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.89
vs STU:7CB: 0.05
Statera BioPharma (STU:7CB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Statera BioPharma Current Ratio Related Terms
Statera BioPharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Statera BioPharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7CB vs NRBO, PALI, BLCM: Current Ratio Comparison
For the Biotechnology subindustry, Statera BioPharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Statera BioPharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Statera BioPharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Statera BioPharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Statera BioPharma (STU:7CB) has a Current Ratio of 0.05 as of Sep. 2022. This is 58% below median its historical median of 0.12. Over the past decade, Statera BioPharma's Current Ratio has ranged from 0.05 to 1.31.
Is Statera BioPharma's Current Ratio too high?
Statera BioPharma's current Current Ratio of 0.05 is 58% below median its 10-year median of 0.12. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 1.31. The Biotechnology industry median Current Ratio is 3.89. Statera BioPharma's value of 0.05 is 98.7% below this industry median. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Current Ratio compare to NRBO and PALI?
Statera BioPharma's Current Ratio of 0.05 can be compared against companies in the Biotechnology industry. The industry median Current Ratio is 3.89. Statera BioPharma's value of 0.05 is 98.7% below this benchmark. Historically, Statera BioPharma's own Current Ratio has ranged from 0.05 to 1.31 over the past decade. While the company's 10-year median is 0.12 vs. the industry median of 3.89, Statera BioPharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Statera BioPharma's current Current Ratio of 0.05 is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Statera BioPharma's current Current Ratio is 0.05, which is 58% below median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STU:7CB) has a current Current Ratio of 0.05. The current Current Ratio is 0.05, which is 58% below median its 10-year median of 0.12 and 98.7% below the Biotechnology industry median of 3.89. Statera BioPharma's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Statera BioPharma (STU:7CB), the current Current Ratio is 0.05 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CB has been successfully added to your 